Adaptimmune Therapeutics Plc
(NASDAQ : ADAP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-2.38%275.201.4%$809.08m
AMGNAmgen, Inc.
-0.56%217.001.3%$492.24m
CELGCelgene Corp.
-0.46%109.901.3%$454.59m
GILDGilead Sciences, Inc.
0.00%63.331.0%$379.06m
ILMNIllumina, Inc.
0.02%298.293.5%$303.29m
VRTXVertex Pharmaceuticals, Inc.
-1.24%204.531.9%$296.06m
REGNRegeneron Pharmaceuticals, Inc.
-2.36%340.092.6%$258.39m
EXASEXACT Sciences Corp.
2.09%79.8924.0%$198.96m
ALXNAlexion Pharmaceuticals, Inc.
-1.62%105.402.0%$180.23m
SGENSeattle Genetics, Inc.
-0.13%112.066.1%$131.37m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.604.3%$115.42m
SRPTSarepta Therapeutics, Inc.
-3.38%97.5914.6%$111.53m
AAgilent Technologies, Inc.
-0.35%76.891.6%$100.75m
MRTXMirati Therapeutics, Inc.
1.65%102.392.3%$88.04m
NBIXNeurocrine Biosciences, Inc.
-1.18%109.605.0%$84.66m

Company Profile

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.